ADC Therapeutics Sponsored Trials
[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine-lpyl Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT04384484
Status: Active, not recruiting
A Phase 1b, Open-label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine-lpyl in Combination With Other Anticancer Agents in Patients with Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)
NCT04970901
Status: Recruiting
[402-201] – A Phase 2 Open-label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine-lpyl in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03589469
Status: Completed
![Image for: [402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)](https://www.adctmedical.com/wp-content/uploads/2025/02/logo_lotis-1.jpg){kind=logo}
[402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)
NCT02669017
Status: Completed
Investigator-Initiated Trials
In addition to ADCT company-sponsored clinical trials, there are independent research studies, known as Investigator-Initiated Trials (IITs). These studies are designed and conducted by external researchers or institutions, not by ADC Therapeutics. Below is a list of ongoing IITs related to our areas of focus. For additional details about these studies, please visit ClinicalTrials.gov using the link provided.
Disclaimer: Please note that ADC Therapeutics is not the sponsor of these studies and does not manage or oversee them. If you are interested in learning more or participating, please contact the research site directly listed on ClinicalTrials.gov.
A phase 2 study of loncastuximab tesirine and rituximab (Lonca-R) followed by DA-EPOCH-R in previously untreated high-risk diffuse large B-cell lymphoma
NCT05600686
Status: Recruiting
Disease Area: DLBCL
Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
NCT06977711
Status: Recruiting
Disease Area: DLBCL
A Phase 2 Study of Loncastuximab Tesirine plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05672251
Status: Recruiting
Disease Area: DLBCL
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR-T cell Therapy
NCT05464719
Status: Recruiting
Disease Area: DLBCL
A Phase 2 study of Loncastuximab tesirine and Rituximab as Bridging Therapy prior to Standard-of-care CD19 CAR T-cell therapy in patients with large B-cell lymphoma
NCT06788964
Status: Recruiting
Disease Area: DLBCL
A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients with Primary and Secondary Central Nervous System Lymphomas
NCT06607549
Status: Recruiting
Disease Area: CSNL
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
NCT04998669
Status: Recruiting
Disease Area: Follicular Lymphoma
A phase 2, open-label, study evaluating safety and efficacy of the Loncastuximab Tesirine in relapsed/refractory marginal zone lymphoma
NCT05296070
Status: Recruiting
Disease Area: Marginal Zone Lymphoma
Phase 1 trial of Loncastuximab Tesirine and venetoclax for treatment of relapsed/ refractory non-Hodgkin lymphoma Disease Area: Non-Hodgkin Lymphoma
NCT05053659
Status: Recruiting
Disease Area: Non-Hodgkin Lymphoma
A Phase II study evaluating Loncastuximab Tesirine in patients with previously treated Waldenström Macroglobulinemia
NCT05190705
Status: Recruiting
Disease Area: Waldenström Macroglobulinemia
A Pilot Study of Loncastuximab Tesirine in Special Populations of Relapsed/Refractory B-Cell Malignancies Disease Area: Variety of B-cell Malignancies
NCT05453396
Status: Recruiting
Disease Area: Variety of B-cell Malignancies